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Abstract
Objective: Autosomal dominant polycystic kidney disease (ADPKD) is a relentlessly progressing form of chronic kidney
disease for which there is no cure. The aim of this study was to characterize Chinese patients with ADPKD and to identify the
factors which predict cyst growth and renal functional deterioration.
Methods: To analyze disease predicting factors we performed a prospective longitudinal observational study in a cohort of
541 Chinese patients with ADPKD and an eGFR $30 ml/min/1.73 m2. Patients were followed clinically and radiologically
with sequential abdominal magnetic resonance imaging (MRI). Clinical characteristics and laboratory data were related to
changes in estimated glomerular filtration rate (eGFR) and total kidney volume (TKV). A linear regression model was
developed to analyze the factors which determine eGFR and TKV changes.
Results: The age range of this unselected cohort ranged from 4 to 77 years. Median follow-up time was 14.3610.6 months.
Although inter-individual differences in eGFR and TKV were large, there was a consistent link between these two
parameters. Baseline log10-transformed TKV and urinary protein/creatinine ratio were identified as the major predictors for a
faster eGFR decline and were associated with a higher TKV growth rate. Interestingly, a lower thrombocyte count correlated
significantly with lower eGFR (r = 0.222) and higher TKV (r = 0.134).
Conclusions: This large cohort of Chinese patients with ADPKD provides unique epidemiological data for comparison with
other cohorts of different ethnicity. In Chinese patients we identified a lower thrombocyte count as a significant predictor of
disease progression. These results are important for the design of future clinical trials to retard polycystic kidney disease
progression.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is a
distinct genetic disease which occurs with variable frequency in all
parts of the world [1,2]. Its prevalence is estimated to average 100
cases per 100’000 population, although recent studies concluded
that the prevalence is closer to orphan diseases, i.e., in the range of
50 per 100’000 [3]. Mutations in two different genes (PKD1 and
PKD2) are known to cause ADPKD [4,5]. Numerous different
mutations in the PKD1 gene which encodes the ciliary protein
polycystin-1 are responsible for 85% of the cases, and mutations in
PKD2 encoding polycystin-2 are responsible for the remaining
15% of the cases [6]. Mutations in both genes cause significant
phenotypic variability, and PKD2 gene mutations generally lead to
milder disease than PKD1 gene mutations [6,7].
Although the clinical description of ADPKD is well known, it
remains difficult to predict the clinical course and the occurrence
of complications. Therefore longitudinal cohorts have been
established to document the long-term clinical course of the
disease and to identify parameters which predict progression. The
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Table 1. Baseline demographics and clinical characteristics of Chinese ADPKD cohort.
Characteristics N Female Male Total
Age (years) 541 39.2612.3 40.0612.0 39.7612.1
Weight (kg) 539 56.569.7 70.8611.6 64.2612.9
Height (cm) 539 160.668.1 173.466.5 167.569.7
BMI (kg/m2) 539 21.863.0 23.563.2 22.763.2
SBP (mm Hg) 403 129.8617.4 132.8616.0 131.4616.7
DBP (mm Hg) 403 86.6611.4 88.1610.1 87.4610.7
History of hypertension 531 56.6% 76.3% 67.2%
Number of antihyper-tensive drugs 522 0.961.1 1.261.0 1.161.0
- ACE or ARB 45.2% 61.1% 53.8%
- CCB 22.6% 26.5% 24.7%
Previous or
current smokers
513 1.7% 30.6% 17.3%
Family history
for ADPKD
509 74.2% 76.4% 75.4%
Presence of
liver cysts
541 73.7% 70.7% 72.1%
Presence of
regular pain
509 39.5% 34.8% 36.9%
History of
macro-hematuria
517 18.7% 27.5% 23.4%
Baseline demographics and clinical characteristics for female (n = 251) and male (n = 290) patients with ADPKD are reported separately, and for both sexes combined
(n = 541). Data show mean 6 standard deviation or relative frequency (%), respectively.
doi:10.1371/journal.pone.0092232.t001
Table 2. Baseline renal parameters and eGFR data stratified by age categories.
Age category years #18 19–30 31–40 41–50 51–60 .60 All
Blood
Creatinine
(n = 502)
mmol/l 84.4681.2 81.2644.1 90.7660.3 103.1646.9 113.2644.1 140.6688.1 98.1656.0
eGFR
(n = 502)
ml/min/1.73 m2 130.9650.2 116.4613.0 105.9613.1 94.2611.8 84.2610.1 75.7614.6 100.4620.1
Yearly eGFR
change
(n = 416)
ml/min/1.73 m2 +7.0626.8 +1.368.0 –0.767.9 –1.867.1 –3.5610.6 –1.362.2 –0.969.6
Cystatin
C (n = 331)
mg/l 0.9260.31 0.9260.56 1.0060.55 1.2360.57 1.4960.66 1.7560.81 1.1760.63
BUN
(n = 503)
mmol/l 6.865.4 5.763.2 5.862.4 6.562.4 7.162.6 8.264.0 6.362.9
Uric acid
(n = 488)
mmol/l 3406109 318686 322691 3636104 3866101 385688 3476100
b2-micro-globulin
(n = 383)
mg/l 1.6961.21 1.6461.06 1.9561.64 2.3561.27 4.1964.69 3.8062.80 2.4562.56
Urine
Protein/
creatinine
ratio (n = 324)
g/g 0.3360.67 0.1460.20 0.1960.34 0.2260.27 0.2660.25 0.3860.30 0.2160.32
Specific
gravity
(n = 253)
g/cm3 1.01860.007 1.02060.007 1.01660.007 1.01560.007 1.01660.007 1.01960.007 1.01660.007
pH (n = 257) 5.5060.37 5.7260.54 5.7060.48 5.7060.55 5.7060.46 5.7060.46 5.6960.50
Baseline laboratory data and eGFR for age categories #18 years (n = 20), 19–30 years (n = 74), 31–40 years (n = 171), 41–50 years (n = 128), 51–60 years (n = 90), and .60
years (n = 19) are reported. To reduce the number of missing values, baseline cystatin C, b2-microglobulin and the protein/creatinine ratio were replaced by the mean of
all measured values from all visits. Data show mean 6 standard deviation.
doi:10.1371/journal.pone.0092232.t002
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best characterized cohort (n = 241) with the longest follow-up is the
cohort of the Consortium for Radiologic Imaging Studies of
Polycystic Kidney Disease (CRISP) in the United States which has
provided important information regarding the main predictors of
renal disease progression [8–10]. Other well characterized
longitudinal cohorts have been set up, including the Swiss
ADPKD (n= 100) [11] and the recently established global
OVERTURE (n of ca. 3000) [12] cohorts, which will continue
to provide important information regarding major determinants of
disease progression. Data generated from these cohorts will also be
essential to define the clinically relevant parameters which are
needed to evaluate the efficacy of novel treatments.
Here we describe the clinical characteristics and the factors
which predict disease progression in a unique longitudinal cohort
of Chinese patients (n = 541) with ADPKD. These data will be
useful to design future clinical trials which endeavor to define
therapies which retard disease progression in ADPKD.
Subjects and Methods
Patient recruitment
The study protocol and consent form were developed, reviewed
and approved by the Kidney Institute of PLA. The study was
approved by the Ethics Committee of the Second Military Medical
University (Shanghai, China). Chinese patients with an established
diagnosis of polycystic kidney disease were identified by a
nationwide search in mainland China. All patients were recruited
at a single nephrology center at Changzheng Hospital (Shanghai,
China). Recruitment started in June 2009, and is ongoing.
Informed written consent was obtained from each potentially
eligible subject or his legal representative prior to enrollment.
Inclusion and exclusion criteria
Patients had to have an established diagnosis of autosomal
dominant polycystic kidney disease (ADPKD) as defined by the
criteria of Pei [13]. There were no age limits, but the eGFR had to
be $30 ml/min/1.73 m2 according to the CKD-EPI formula for
Figure 1. Renal function in different age categories of ADPKD patients. A) Creatinine (mmol/l) for age categories #18 years (n = 20), 19–30
years (n = 74), 31–40 years (n = 171), 41–50 years (n = 128), 51–60 years (n = 90), and .60 years (n = 19). B) eGFR (ml/min/1.73 m2) for age categories
#18 years (n = 20), 19–30 years (n = 74), 31–40 years (n = 171), 41–50 years (n = 128), 51–60 years (n = 90), and .60 years (n = 19). Boxes show the
median and the 25th and 75th percentile. Whiskers extend to the farthest points that are not outliers (i.e., that are within 3/2 times the interquartile
range) and dots indicate outliers. C) Spaghetti plots for course of creatinine and D) eGFR over entire observation time in individual patients.
doi:10.1371/journal.pone.0092232.g001
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adults or the Schwarz equation for children. Patients on dialysis
treatment or having received a kidney transplant were excluded.
Subjects were ineligible to participate if they were unable to
undergo breath-held magnetic resonance imaging (MRI), or had
contraindications for MRI such as having a cardiac pacemaker,
metallic foreign bodies or aneurysmal clips. Patients were also
excluded if they had systemic diseases other than hypertension that
could potentially affect renal function. Female patients who were
pregnant, lactating or less than 6 months postpartum were also
excluded.
Schedule of examinations
Medical histories were taken and physical examinations were
performed at the time of screening and enrollment at Changzheng
Hospital in Shanghai. Enrolled subjects were scheduled for a 2-day
evaluation visit, and were then seen at 6 months intervals. Blood
and urine samples were collected at each visit. Abdominal MRI
scans were obtained at baseline and at each follow-up visit, using a
previously described protocol [11]. Total kidney volumes (TKV)
and total renal cyst volumes (TCV) were measured twice by two
independent observers on an interactive workstation (Advantage
Windows Workstation; GE Medical Systems Europe, Buc,
France).
Statistical analyses
All medical data were anonymized and transferred to a
spreadsheet. Descriptive analyses were performed for all baseline
data (mean6SD, median, range). Female and male patients were
compared with a two-tailed Fisher’s exact test for nominal
variables and with a two-tailed Mann-Whitney U test for
quantitative variables. For the correlation analyses, the Pearson
product-moment correlation coefficient or Spearman’s rho was
calculated.
A multiple linear regression was run with yearly eGFR change
or yearly TKV growth (%) as dependent variable, and the
following independent variables: age, sex, observation time, history
of hypertension, intake of antihypertensive drugs, SBP, DBP,
episodes of macrohematuria, baseline eGFR, protein/creatinine
ratio, baseline TKV and baseline thrombocyte count. A total of
279 patients aged .18 years and #60 years with valid data for all
variables of the model were included. For the variables SBP, DBP,
episodes of macrohematuria and thrombocyte count, missing
values were imputed by data from the next following visit. Overall,
the missingness of data was dependent on observation time, i.e.,
patients with fewer visits and thus shorter observation time had
more missing data. Except for observation time, Little’s test
indicated that data were missing completely at random (P=0.105).
For predictor selection, a stepwise forward and backward
selection using the exact Akaike Information Criterion (AIC) was
performed. In the model with yearly eGFR change as dependent
variable, baseline eGFR was also included as additional control-
ling variable. Nonlinearity was evaluated with component plus
residual plots, normality was checked with a Q-Q plot for
studentized residuals. Homoscedasticity was evaluated with a
studentized residuals versus fitted values plot and with the non-
constant error variance test. The outlier test and Cook’s D plot
were used to check for outliers and influential points. Several
measures had to be taken to meet the assumptions of linear
regression. A normal distribution of the residuals was achieved by
windsorizing the dependent variable. Linearity was reached by
log10-transforming baseline TKV and protein/creatinine ratio.
For the model with yearly TKV change as dependent variable,
heterogeneity of variance could be reduced considerably by
introducing observation time into the model. However, as the non-
constant variance score test was still of borderline significance
(P=0.059), a regression with robust standard errors was run.
All analyses were done using SPSS Version 20 except for the
regression, which was performed in R version 2.15.2.
Figure 2. Thrombocytes were correlated to age, TKV and eGFR
in ADPKD patients. A) Scatter plot between age and thrombocytes
(n = 399). Pearson correlation coefficient is –0.286 (P,0.001). B) Scatter
plot between thrombocytes and log10 TKV (n = 394). Pearson correlation
coefficient is –0.134 (P= 0.008). C) Scatter plot between thrombocytes
and eGFR (n = 391). Pearson correlation coefficient is 0.222 (P,0.001).
doi:10.1371/journal.pone.0092232.g002
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Results
General characteristics of the cohort
The Chinese ADPKD cohort represents an ongoing longitudi-
nal study. In the present interim report, we analyzed 541 patients
who were enrolled between June 2009 and December 2011.
Patients were followed up every six months. The mean follow-up
duration was 14.3610.6 months (median 16 months, range 0–38
months).
The recruitment strategy of the cohort subjects was designed to
allow for the inclusion of a broad age range of patients with
ADPKD, including children. Table 1 shows the baseline
demographic and clinical characteristics of the cohort, stratified
for male and female patients. The mean age was 40 years (range 4
to 77 years). Seventy-five percent of the patients had a positive
family history for ADPKD. The average disease burden was
important. Two thirds of the patients were hypertensive, taking on
average 1.161.0 antihypertensive drugs (range 0–5). Approxi-
mately half of the patients used angiotensin converting enzyme
inhibitors (ACEI) or angiotensin receptor blockers (ARB) and a
quarter of the patients used calcium channel blockers (CCB) to
treat hypertension. Approximately three quarters of the patients
had liver cysts, 37% complained of chronic pain, and 23% have
had episodes of macrohematuria. Compared to male patients,
female patients had a lower BMI (P,0.001), were less often
hypertensive (P,0.001), had slightly more often liver cysts
(P=0.444) and more pain (P=0.311), but less often macrohema-
turia (P=0.035). Frequency distributions for age, antihypertensive
drugs, diastolic blood pressure (DBP), systolic blood pressure
(SBP), eGFR, and TKV are shown in the Figures S1A to S1F.
Characteristics of renal function in the cohort
Table 2 displays the baseline renal parameters (blood and
urine), stratified for six different age categories. In the age range
between 19 and 60, a gradual rise in the serum levels of creatinine,
cystatin C, BUN, uric acid and b2-microglobulin was found with
increasing age. Likewise, the eGFR (creatinine-based CKD-EPI
formula) showed a steady decrease in these four age categories.
Correlation analysis confirmed that age was negatively correlated
with eGFR (see below). Of note, the yearly eGFR decline became
more pronounced with increasing age, amounting to –3.5 ml/
min/1.73 m2 per year in the age category of 51 to 60.
Furthermore, the urine protein/creatinine ratio also increased
with age, whereas the urine specific gravity (1.01660.007 g/cm3)
and the urine pH (5.6960.50) did not change substantially in the
different age groups. Table S1 in File S1 provides additional eGFR
data for reference.
Figure 1 graphically depicts the distribution of serum creatinine
and eGFR in the different age categories (Fig. 1A and 1B), and the
change over time in serum creatinine and eGFR in individual
patients (Fig. 1C and 1D). Overall, there was a wide spectrum of
eGFR in all age categories. Of note, a pronounced creatinine rise
and eGFR decline was apparent in many patients in all age
categories.
Regarding other laboratory data such as electrolytes, lipids and
hematological parameters, no apparent differences could be
detected among the different age categories, except for the
hemoglobin level and more importantly the thrombocyte count
which were both lower in the advanced age groups (Table S2 in
File S1). The correlation analysis confirmed that the thrombocyte
count was negatively correlated with age (Fig. 2A). Moreover, the
thrombocyte count was found to be negatively correlated with
log10-transformed TKV and positively with eGFR (Fig. 2B and
2C). Out of 399 patients, 60 (15.0%) had a baseline thrombocyte
count below 145 G/l and were thus clearly thrombocytopenic.
Characteristics of renal volume growth in the cohort
The mean TKV for the entire cohort amounted to
126561002 cm3 at baseline, and the mean TCV was
8696929 cm3, corresponding on average to 58621% of the
TKV. The mean yearly increase of TKV amounted to
726183 cm3, representing 4.6610.2% TKV growth per year
(Table 3). The large standard deviations are noticeable, illustrating
the large inter-individual differences of the renal volume in the
cohort. On average, female patients had a lower TKV than males
Table 3. Baseline kidney and cyst volumes and yearly volume growth rates stratified by age.
Age category years #18 19–30 31–40 41–50 51–60 .60 All
Baseline TKV
N 23 81 180 134 95 19 532
cm3 4586385 8426646 11266739 14956909 15756948 218062774 126561002
Yearly TKV growth
N 15 61 157 99 76 13 421
cm3/yr 406174 656153 716185 836193 616154 1306328 726183
%/yr 2.3624.3 4.9610.8 5.469.6 4.869.3 3.667.3 1.1611.5 4.6610.2
Baseline TCV
N 23 81 180 134 95 19 532
cm3 1876359 4646602 7196652 10726857 11896858 181162613 8696929
Yearly TCV growth
N 15 61 157 99 76 13 421
cm3/yr 346180 616132 706177 676201 526180 1596395 666188
%/yr 17.8659.3 10.6618.4 11.2619.6 6.8614.9 4.5611.9 2.9619.0 8.9620.1
Baseline kidney volumes (TKV and TCV) and yearly volume growth rates for age categories #18 years, 19–30 years, 31–40 years, 41–50 years, 51–60 years, and.60 years
are reported. Data show mean 6 standard deviation.
doi:10.1371/journal.pone.0092232.t003
Chinese ADPKD Cohort
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(10816891 vs. 142761065 cm3, P,0.001), and a lower yearly
TKV growth rate (3.3611.3 vs. 5.769.2%, P=0.003).
Figure 3A and 3B graphically depict the TKV and the TCV in
the different age categories, revealing that TKV and TCV
increased up to the age of 60. TKV was indeed positively
correlated with age (see below). Figures 3C, 3D and 3E illustrate
that there was a tight correlation between RKV and LKV
(r=0.902), between RCV and LCV (r=0.857), and between TKV
Figure 3. TKV and TCV in different age categories, and the correlations between kidney volumes (KV) and cyst volumes (CV). A) TKV
and B) TCV for age categories#18 years (n = 23), 19–30 years (n = 81), 31–40 years (n = 180), 41–50 years (n = 134), 51–60 years (n = 95), and.60 years
(n = 19). Boxes show the median and the 25th and 75th percentile. Whiskers extend to the farthest points that are not outliers (i.e., that are within 3/2
times the interquartile range) and dots indicate outliers. C) Scatter plot between RKV and LKV (n = 532). The regression line is defined by
LKV= 0.337+0.889*RKV. Pearson correlation coefficient is 0.902 (P,0.001). D) Scatter plot between RCV and LCV (n = 530). Pearson correlation
coefficient is 0.857 (P,0.001). E) Scatter plot between baseline TKV and baseline TCV (n = 532). Pearson correlation coefficient is 0.951 (P,0.001).
doi:10.1371/journal.pone.0092232.g003
Chinese ADPKD Cohort
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and TCV (r=0.951). The Tables S3 and S4 in File S1 show
additional kidney volume data for reference.
Figure 4 shows the TKV change over time in individual
patients. Overall, the range of TKV increased with advancing age,
reflecting large inter-individual differences. Of note, steep
increases in TKV were found in all age categories and especially
in patients with baseline TKV greater than 1500 cm3. In Figure
S2, baseline TKV and the yearly TKV growth rate are lined up in
ascending order, with the corresponding yearly TKV growth rate
and baseline TKV being displayed in the graph above, illustrating
that the growth rate appeared to increase with increasing baseline
TKV.
Correlations between TKV and eGFR
There was a significant negative correlation between baseline
TKV and eGFR for the different age categories between age 19
and 60 (Fig. 5A). For all patients between age 19 and 60 the r
amounted to –0.596 (p,0.001). TKV correlated best with eGFR
in the age group 19–30 (r=–0.622) and was least in the age group
51–60 (r=–0.382). As mentioned above, age correlated positively
with log10-transformed TKV (r=0.439) and negatively with eGFR
(r=–0.645) (Fig. 5B). However, there was only a very weak
correlation between the yearly eGFR change and the yearly TKV
volume growth (Fig. 6A and 6B).
Analysis of predictors of progression
Table 4 shows the results of the linear regression with yearly
eGFR change as the dependent variable. The model explains only
19% of the total variance. We identified a highly significant
association of log10 protein/creatinine ratio and also baseline log10
TKV with the yearly decrease of eGFR. Age and thrombocyte
count were also significantly associated. At first sight the influence
of history of hypertension and intake of antihypertensive drugs on
eGFR change seems complicated. When developing the model we
found that the association between the unadjusted estimate of
history of hypertension and the yearly eGFR change was negative.
When controlling for intake of antihypertensive drugs the
association turned into a positive one. Since the intake of
antihypertensive drugs may reflect a higher disease severity, the
addition of this latter parameter to the model seems to be justified.
Table 5 shows the results of the linear regression with percental
yearly TKV change as dependent variable. This model explains
only 16% of the variance. Interestingly, age was identified as a
highly significant predictor for reduction in the percentage rate of
TKV, possibly as a reflection of a higher probability of cyst
ruptures. In addition, the intake of antihypertensive drugs, male
sex, lower thrombocyte count and log10 protein/creatinine were
significant predictors for yearly TKV change. Although the
dependent variable already accounted for baseline TKV insofar
it represents the percental increase, baseline TKV was also
retained in the regression model. Paradoxically, a lower diastolic
blood pressure was associated with a higher yearly TKV change. It
is however difficult to estimate the true effect of blood pressure on
TKV change since in most hypertensive patients, blood pressure is
controlled by antihypertensive drugs. The regression model for
TKV change was hampered by heterogeneity of variance, which
Figure 4. Spaghetti plot for TKV over entire observation time in individual patients (n =421).
doi:10.1371/journal.pone.0092232.g004
Chinese ADPKD Cohort
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Figure 5. Correlations among TKV, eGFR and age in ADPKD patients. A) Scatter plots between baseline TKV and eGFR. The upper left panel
shows patients of age 19–30 years (n = 72), the upper right panel patients of age 31–40 years (n = 171), the lower left panel patients of age 41–50
years (n = 127), and the lower right panel patients of age 51–60 years (n = 90). B) Scatter plots between age and baseline TKV (n = 532) (left panel), and
between age and eGFR (n = 502) (right panel).
doi:10.1371/journal.pone.0092232.g005
Chinese ADPKD Cohort
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could be reduced considerably by introducing observation time
into the model.
Discussion
A majority of patients with ADPKD reach end-stage renal
disease (ESRD) in the 5th or 6th decade of life [14,15], but renal
insufficiency may occur much earlier or later. While years ago it
was felt that the course of polycystic kidney disease was totally
unpredictable [16], more recent studies have shown that mutations
in PKD1, male sex, early onset hypertension and macrohematuria,
baseline GFR, albuminuria, renal cyst volume and uric acid are
among the most important factors which predict more severe
disease progression and an earlier onset of ESRD [8–11,17–23].
Large cross-sectional and retrospective studies of ADPKD
cohorts have provided fundamental information on the clinical
course and the predictive factors, but their value has been limited
by the lack of prospective data for GFR decline and cyst growth.
Thus it is only recently – and particularly in association with the
advent of CT- and MRI-based radiological techniques that allow
precise measurement of renal volume changes – that truly
prospective cohorts have been set-up to elucidate the character-
istics of polycystic kidney disease progression. The invaluable
CRISP cohort has been established between 2001 and 2005 and
represents the most detailed cohort of 241 patients with ADPKD
[8,24]. Recently, 6- and 8-year follow-up data have been reported,
providing important insight regarding the factors which determine
the decline in GFR and TKV growth [10,25].
Here we describe a large longitudinal clinical cohort of 541
Chinese patients with ADPKD. Our data allow not only
verification but also extension of the data from CRISP [8-10]
and other cohorts [11,12,26]. The Chinese cohort is as detailed as
the CRISP cohort, yet more than twice the size and specific for the
Chinese population, but with only a short observation time.
Contrasting with CRISP [8] and the smaller SUISSE ADPKD
cohort [11], the Chinese cohort spans a broader age range which
includes pediatric and older patients, with a majority of patients
(n = 497) in a wider adult age range (19–60 years). This has the
advantage to provide prospective data for additional age
categories, but introduces some heterogeneity of the data,
wherefore we have limited the analysis of the progression data
to the age range between 19 and 60. Limitations of the cohort are
its short follow-up time, the reliance on estimated rather than
measured GFR, the lack of mutational analyses, and the fact that
the study population is confined to China.
Figure 6. Correlations between yearly TKV growth and eGFR
change in ADPKD patients. A) Scatter plot between yearly eGFR
change and yearly TKV volume growth (cm3) (n = 372). Spearman’s rho
is –0.119 (P= 0.022). Only patients .18 years and #60 years are
included. B) Scatter plot between yearly eGFR change and yearly TKV
volume growth (%) (n = 372). Spearman’s rho is –0.055 (P= 0.288). Only
patients .18 years and #60 years are included.
doi:10.1371/journal.pone.0092232.g006
Table 4. Linear regression model with 97% windsorized yearly eGFR change as dependent variable.
Coefficients Estimate Standard error P-value Change of coefficient by
Adjustment in yearly eGFR
change (ml/min/1.73m2/year)
Log10 protein/ creatinine –4.572024 0.941120 ,0.001 1% –0.020
Log10 baseline TKV –4.992699 1.478459 ,0.001 1% –0.022
Thrombocyte count –0.012648 0.005818 0.031 1 G/l –0.013
Age –0.113218 0.046569 0.016 1 year –0.113
History of hypertension 2.350887 1.223246 0.056 Presence vs. absence 2.350
Intake of antihypertensive drugs –1.970294 1.199285 0.102 Presence vs. absence –1.970
Baseline eGFR –0.036897 0.034818 0.290 1 ml/min/1.73 m2 –0.037
Intercept 20.274693 7.778006 0.010
Adjusted R2 was 0.1943, F-statistic was 10.58 on 7 and 271 DF (P,0.001).
doi:10.1371/journal.pone.0092232.t004
Chinese ADPKD Cohort
PLOS ONE | www.plosone.org 9 March 2014 | Volume 9 | Issue 3 | e92232
In agreement with the CRISP and the SUISSE ADPKD results,
our data confirm that ADPKD is more severe in male than in
female patients, and that there is an age-dependent decrease of
eGFR and increase in TKV which extends to older patients.
Consistent with the two other cohorts we found similar values for
eGFR and TKV and the yearly changes thereof in their respective
age range. Thus at a mean age of 32.468.9 years, CRISP reported
a baseline TKV of 10766670 cm3 and a 5.363.9% yearly
increase of TKV [8]. At a mean age of 31.266.4 years, SUISSE
ADPKD reported a TKV of 10036568 cm3 and an extrapolated
yearly TKV growth of 5.469.5% [11]. Although not precisely
comparable we also found a mean TKV around 1000 cm3 and an
average yearly TKV growth of approximately 5.2% in the age
category between 19 and 40 years. Furthermore the baseline
eGFR and the yearly eGFR changes seen in CRISP and SUISSE
ADPKD were similar to the Chinese patients in the respective age
categories. Taken together this suggests that the impact of the
Chinese ethnicity on ADPKD is negligible. As a consequence,
clinical trials in Chinese ADPKD patients might rely on similar
assumptions regarding the definition of clinical endpoints.
Earlier prospective studies in patients with ADPKD have shown
that GFR and kidney volume correlate [8,10,26–28]. Although the
follow-up time in our cohort was short (14.6610.6 months in the
adult population of 19–60 years) we could compute the yearly
changes in TKV and eGFR in an extended number of age
categories. An important finding was that many patients displayed
a pronounced and unpredictable creatinine rise and eGFR
decline, and this was apparent in all age categories. This suggests
that it remains difficult to predict the course of the renal function
in individual patients. Furthermore, steep increases in TKV were
also found in all age categories and especially in patients with
baseline TKV greater than 1500 cm3. For reasons not yet well
understood it appears that the predictability of the change in TKV
is as difficult as the predictability of changes in eGFR. This is also
illustrated by the poor correlation between the yearly eGFR and
TKV changes in our cohort, and by the data in Figure S2 which
show that there are large excursions (increases and decreases) of
TKV growth which do not correlate well with increasing baseline
TKV. As longer follow-up times become available in our cohort
the sudden volume changes - which could be due to hemorrhage
or cyst rupture – might become less obvious, and the average
TKV growth rate should become more reliable.
The linear regression analysis revealed that the yearly decrease
of eGFR was significantly associated with higher log10 protein/
creatinine ratio, log10 baseline TKV and age. On the other hand
the linear regression analysis with percental yearly TKV change as
dependent variable revealed that the intake of antihypertensive
drugs, male sex, lower thrombocyte count and higher log10
protein/creatinine were associated with this variable. The fact that
the TKV change was dependent on observation time implicates
that the variance is larger for patients with short observation
periods and decreases with longer observation periods. This might
possibly be explained by the fact that bursting cysts lead to lower
TKV at shorter observation periods but less so when the
observation time is longer. With increasing observation time, the
trend towards a steady TKV growth might get clearer. Conse-
quentially and as stated above, it is essential for the study of TKV
growth to maximize follow-up times in order to reduce the ‘‘noise’’
caused by ruptured cysts.
An important finding which has not been described in other
cohorts was the identification of a reduced thrombocyte count in
older age groups. Although there is a small decrease of the
thrombocyte count with increasing age in the normal population,
we found a 32% lower thrombocyte count (–71 G/l) in the oldest
age group when compared with the youngest cohort patients.
Furthermore we found a positive correlation between thrombocyte
count and eGFR, and a negative correlation with TKV. Bath et al.
also described a reduced number of thrombocytes in ADPKD
patients (average age 31 years) in comparison with matched
control subjects (–63 G/l), in addition to an increased platelet
volume (median 8.4 vs 8.0 fl), suggesting that there is enhanced
platelet consumption in ADPKD [29]. Our regression analysis
showed that the TKV growth rate was significantly influenced by
the thrombocyte count, suggesting that platelets might be
implicated in the pathogenesis of cyst growth. Further studies
need to be performed to define the pathogenic role of thrombo-
cytes in ADPKD.
In conclusion, we describe the clinical characteristics and the
factors that predict disease progression in a large cohort of Chinese
patients with ADPKD. Among the progression factors we found
that log10-transformed TKV and protein/creatinine ratio signif-
icantly predicted eGFR loss and were associated with TKV
growth. Furthermore we identified the decreased thrombocyte
count as a novel parameter which is associated with more
advanced renal impairment, higher TKV and higher TKV
Table 5. Linear regression model with 96.4% windsorized yearly TKV change as dependent variable.
Coefficients Estimate Standard error P-value
Change of
coefficient by
Adjustment in yearly
TKV change (%/year)
Log10 protein/creatinine 2.552477 1.295340 0.050 1% 0.011
Log10 baseline TKV 3.315135 1.961758 0.092 1% 0.014
Thrombocyte count –0.014728 0.007203 0.042 –1 G/l 0.015
Male sex 1.846426 0.806099 0.023 male vs. female 1. 846
Intake of anti-hypertensive drugs 2.157377 0.884859 0.015 presence vs. absence 2.157
Age –0.235288 0.065427 ,0.001 1 year –0.235
Diastolic blood pressure –0.083163 0.040440 0.041 1 mm Hg –0.083
Baseline eGFR –0.072392 0.053032 0.173 1 ml/min/1.73 m2 –0.072
Observation time 1.634095 0.905810 0.072 1 year 1.634
Intercept 18.597347 11.763321 0.115
Adjusted R2 was 0.1612, F-statistic was 6.935 on 9 and 269 DF (P,0.001).
doi:10.1371/journal.pone.0092232.t005
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growth. The Chinese cohort provides an important data source for
the understanding of ADPKD disease progression and the design
of future clinical trials in China.
Supporting Information
Figure S1 Frequency distributions for different catego-
ries. A) frequency distributions for age (years) (n = 541); B)
frequency distributions for number of prescribed antihypertensive
drugs (n = 522); C) frequency distributions for diastolic blood
pressure (DBP) in mm Hg (n= 403); D) frequency distributions for
systolic blood pressure (SBP) in mm Hg (n = 403); E) frequency
distributions for estimated glomerular filtration rate (eGFR) in ml/
min/1.73 m2 (n = 502); F) frequency distributions for total kidney
volume (TKV) ,5000 in cm3 (n= 529).
(TIF)
Figure S2 Correlations between baseline TKV and
yearly TKV growth. A) Baseline TKV (cm3) lined up in
ascending order, with corresponding yearly TKV growth (cm3)
depicted in the graph above. B) Yearly TKV growth (cm3) lined up
in ascending order with corresponding baseline TKV (cm3)
depicted in the graph above. Only patients .18 years and #60
years are included (n= 393).
(TIF)
File S1 Supporting Tables. Table S1: Table shows the eGFR
and the yearly changes of the eGFR, stratified by age categories.
The eGFR was calculated according to the CKD-EPI formula in
adults and according to the Schwarz formula in children. Table
S2: Data show mean 6 standard deviation. Table S3: Table
reports baseline kidney volumes in cm3. RKV, right kidney
volume; LKV, left kidney volume; TKV, total kidney volume.
Table S4: Table reports baseline cyst volumes in cm3. RCV, right
cyst volume; LCV, left cyst volume; TCV, total cyst volume.
(DOC)
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